Trafermin
From PeptidePlaza, the free peptide reference · Entry #1162 · Nootropic · Sources fetched 2026-09-11 · Editorial standards
Trafermin is a nootropic research peptide. Trafermin is an FDA-approved fibroblast growth factor receptor 2 agonist. It is studied for its role in tissue repair and regeneration.
Trafermin is a fibroblast growth factor receptor 2 agonist, meaning it activates this receptor. It is an FDA-approved compound. Research into trafermin has explored its potential applications in various conditions, including periodontitis, diabetic foot ulcers, tympanic membrane perforation, and skin ulcers, all of which have reached Phase 3 clinical trials. Studies have also investigated its safety following intracordal injection and its effects in models of oronasal fistula. The compound's role in vocal fold paralysis treatment has also been a subject of recent literature.
1 Mechanism of action
Fibroblast growth factor receptor 2 agonist (agonist)
Primary targets: Fibroblast growth factor receptor 2
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Periodontitis
- Diabetic Foot
- Tympanic Membrane Perforation
- Skin Ulcer
3 Chemical and physical properties
| Purity (typical) | Not independently verified |
|---|---|
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
| Receptors / targets | Fibroblast growth factor receptor 2 |
4 Research studies (8)
- Evaluation of Safety After Intracordal Basic Fibroblast Growth Factor Injection
Journal of voice : official journal of the Voice Foundation (2025) - Changes in serum basic fibroblast growth factor concentration following intracordal injection
Laryngoscope investigative otolaryngology (2023) - Time for a neurorestorative therapy in stroke
Expert opinion on biological therapy (2012) - Visual and histological evaluation of the effects of trafermin in a dog oronasal fistula model
The Journal of veterinary medical science (2022) - Timing of Intracordal Trafermin Injection in Patients With Vocal Fold Paralysis: Recommendations for a New Treatment Time Course
Journal of voice : official journal of the Voice Foundation (2024) - Predictors of Voice Improvement After Intracordal Trafermin Injection in Vocal Fold Paralysis
The Laryngoscope (2025) - Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial
Cerebrovascular diseases (Basel, Switzerland) (2002) · RCT - [Neuroprotective agents]
Neurologia (Barcelona, Spain) (1999) · Review
5 Safety and risk profile
5.1 Regulatory status
Trafermin is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.
6 Frequently asked questions
- What is Trafermin?
- Trafermin is a compound classified as a fibroblast growth factor receptor 2 agonist. It is an FDA-approved substance, indicating its established use in medical contexts.
- How does Trafermin work?
- Trafermin functions as an agonist of the fibroblast growth factor receptor 2. This means it activates the receptor, which is involved in various cellular processes, including cell growth, proliferation, and differentiation, contributing to tissue repair and regeneration.
- What is Trafermin used for?
- Trafermin is studied for several conditions, including periodontitis, diabetic foot, tympanic membrane perforation, and skin ulcers. These indications have all progressed to Phase 3 clinical trials, suggesting its potential therapeutic applications in tissue repair.
- Is Trafermin FDA approved?
- Yes, Trafermin is an FDA-approved compound. It received its first approval in 2016, confirming its regulatory status for medical use.
7 References
- Trafermin — molecule record ChEMBL. View source
- Trafermin — published literature (47 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Trafermin.
Shares growth and factor pharmacology
An angiotensin IV derivative reported to be orders of magnitude more potent than BDNF at driving synaptogenesis. Its mechanism runs through c-Met — the same receptor that drives many cancers.
Shares growth and factor pharmacology
Conbercept is a vascular endothelial growth factor (VEGF) inhibitor, primarily studied for ophthalmic conditions.
Shares growth and factor pharmacology
Becaplermin is a recombinant human platelet-derived growth factor, functioning as a platelet-derived growth factor receptor agonist. It is FDA-approved for the treatment of lower extremity diabetic neuropathic ulcers.
Shares fibroblast and growth pharmacology
The same fifteen amino acids as BPC-157, paired with an arginine counterion instead of acetate. Marketed as a successor compound; chemically, it is a salt form.
Shares growth and factor pharmacology
Telbermin is a vascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) agonist currently in Phase 2 clinical trials.